Gland Pharma shareholders and shareholding pattern
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2,826.80down ₹23.60 (0.83%)BSE ₹2,825.35
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,850.40.
52-week range of traded prices to 23 Oct 2026
₹1,573.60Low, 16 Mar 2026₹3,171.00High, 7 Oct 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹46,645 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 41.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 4.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,23,05755.6% delivered
Who owns Gland Pharma, filing by filing
Per cent of the company's shares. Every filing on record, from Dec 2020; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters45.75%
- Foreign institutions10.36%
- Indian institutions33.21%
- Governments0.01%
- Individuals and others10.66%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Governments
- Individuals and others
| Per cent | Dec 2020Filed 18 Jan | Mar 2021Filed 17 Apr | Jun 2021Filed 6 Jul | Sep 2021Filed 16 Oct | Dec 2021Filed 13 Jan | Mar 2022Filed 15 Apr | Jun 2022Filed 14 Jul | Sep 2022Filed 18 Oct | Dec 2022Filed 11 Jan | Mar 2023Filed 14 Apr | Jun 2023Filed 17 Jul | Sep 2023Filed 18 Oct | Dec 2023Filed 12 Jan | Mar 2024Filed 15 Apr | Jun 2024Filed 15 Jul | Sep 2024Filed 17 Oct | Dec 2024Filed 20 Jan | Mar 2025Filed 15 Apr | Jun 2025Filed 18 Jul | Sep 2025Filed 15 Oct | Dec 2025Filed 16 Jan | Mar 2026Filed 17 Apr | Jun 2026Filed 20 Jul | Sep 2026Filed 16 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.36% | 58.25% | 58.14% | 58.02% | 58.00% | 58.00% | 57.87% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% | 45.75% | |
| Foreign promoters | 58.36% | 58.25% | 58.14% | 58.02% | 58.00% | 58.00% | 57.87% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% | 45.75% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 41.64% | 41.75% | 41.86% | 41.97% | 42.00% | 42.00% | 42.13% | 42.14% | 42.14% | 42.14% | 42.14% | 42.14% | 42.14% | 42.14% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.23% | 54.25% |
| Shares in issue | 16,32,82,823 | 16,35,92,923 | 16,39,04,723 | 16,42,37,173 | 16,43,02,723 | 16,43,02,723 | 16,46,55,923 | 16,46,88,423 | 16,46,90,223 | 16,47,00,823 | 16,47,00,823 | 16,47,00,823 | 16,47,01,923 | 16,47,10,523 | 16,47,51,723 | 16,47,51,723 | 16,47,51,723 | 16,47,56,423 | 16,47,56,423 | 16,47,56,423 | 16,47,56,423 | 16,47,56,423 | 16,49,59,682 | 16,50,10,854 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 11,40,85,855 | 11,43,95,955 | 11,40,85,855 | 11,40,85,855 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Promoters' shares locked in | 9,52,93,934 | 9,52,93,934 | 9,52,93,934 | 9,52,93,934 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Gland Pharma promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Fosun Pharma Industrial Pte. Ltd, 45.75%.Promoter buying and selling
| Holder | ||
|---|---|---|
| Fosun Pharma Industrial Pte. LtdForeign companies and others | 45.75% | 7,54,96,894 |
| Regal Gesture LimitedForeign companies and others | 0.00% | 10 |
| Lustrous Star LimitedForeign companies and others | 0.00% | 10 |
| Fosun Industrial Co LimitedForeign companies and others | 0.00% | 10 |
| Ample Up LimitedForeign companies and others | 0.00% | 10 |
No promoter shares are reported as pledged.
Largest public holders of Gland Pharma, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding Gland Pharma
| Holder | Dec 2020Filed 18 Jan | Mar 2021Filed 17 Apr | Jun 2021Filed 6 Jul | Sep 2021Filed 16 Oct | Dec 2021Filed 13 Jan | Mar 2022Filed 15 Apr | Jun 2022Filed 14 Jul | Sep 2022Filed 18 Oct | Dec 2022Filed 11 Jan | Mar 2023Filed 14 Apr | Jun 2023Filed 17 Jul | Sep 2023Filed 18 Oct | Dec 2023Filed 12 Jan | Mar 2024Filed 15 Apr | Jun 2024Filed 15 Jul | Sep 2024Filed 17 Oct | Dec 2024Filed 20 Jan | Mar 2025Filed 15 Apr | Jun 2025Filed 18 Jul | Sep 2025Filed 15 Oct | Dec 2025Filed 16 Jan | Mar 2026Filed 17 Apr | Jun 2026Filed 20 Jul | Sep 2026Filed 16 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hdfc Life Insurance Company LimitedInsurance companies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.51% |
| Government Pension Fund GlobalForeign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.42% | 1.49% | 1.34% | 1.36% | 1.36% | 1.34% | 1.32% |
| Rp Advisory Services Private LimitedCompanies | 3.78% | 3.77% | – | 3.75% | – | – | – | – | – | – | – | – | 3.74% | 3.74% | – | – | – | – | – | – | – | – | – | – |
| Nicomac Machinery Private LimitedCompanies | – | – | – | – | – | 5.81% | 1.93% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | – | – | – | – | – | – | – | – | – | – |
| R P Advisory Services Private Limited-Trustee of Empower Discretionary TrustCompanies | – | – | 2.62% | – | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | – | – | – | – | – | – | – | – | – | – | – | – |
| R P Advisory Services Private Limited-Trustee of Nilay Discretionary TrustCompanies | – | – | 1.14% | – | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | – | – | – | – | – | – | – | – | – | – | – | – |
| Government of SingaporeInstitutions Foreign Portfolio Investor | 2.66% | 2.23% | 1.54% | 1.21% | 1.11% | – | 1.05% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| New World Fund IncInstitutions Foreign Portfolio Investor | – | – | – | 1.27% | 1.27% | 1.27% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Gland Celsus Bio Chemicals Private LimitedOther non-institutions | 6.15% | 6.14% | 6.13% | 6.12% | 6.12% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Smallcap World Fund, IncInstitutions Foreign Portfolio Investor | 1.21% | 1.20% | 1.20% | 1.20% | 1.20% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here: each fund's holding is on the Mutual funds tab, from its own portfolio. A dash is a filing that did not name the holder, which includes holding under one per cent.